Immediate Impact
63 standout
Citing Papers
The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
2025 Standout
Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
2025 Standout
Works of Xiaoli Chai being referenced
Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial
2020 Standout
A multicenter phase II study of donafenib in patients with advanced hepatocellular carcinoma.
2017
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Xiaoli Chai | 333 | 300 | 54 | 155 | 10 | 571 | |
| Damir Begic | 354 | 457 | 44 | 150 | 9 | 600 | |
| Mirelis Acosta-Rivera | 374 | 449 | 57 | 144 | 16 | 629 | |
| R. T. Ottow | 355 | 248 | 54 | 71 | 10 | 598 | |
| D. Jaeger | 359 | 187 | 92 | 56 | 17 | 547 | |
| Sean Cleary | 110 | 214 | 74 | 111 | 12 | 619 | |
| Erik von Seth | 169 | 178 | 82 | 40 | 19 | 594 | |
| Ingvild Moberg | 414 | 265 | 92 | 112 | 6 | 645 | |
| N. J. Robert | 257 | 193 | 54 | 26 | 17 | 557 | |
| Adarsh Joshi | 168 | 250 | 184 | 139 | 18 | 621 | |
| Kathrin Glatz | 330 | 39 | 97 | 54 | 12 | 572 |
All Works
Loading papers...